Domov › Rak dojke › Wisconsin › Madison
Klinične študije za Rak dojke v Madison, WI
22 študij za Rak dojke išče udeležence na lokacijah v Madison in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- University of Wisconsin Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Vključevanje udeležencevFaza 2
- UW Health Carbone Cancer Center, Madison
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Vključevanje udeležencevFaza 2
- University of Wisconsin, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Wisconsin Institute for Medical Research, Madison
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Vključevanje udeležencevFaza 3
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Vključevanje udeležencevFaza 3
- University of Wisconsin-Madison ( Site 0024), Madison
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Vključevanje udeležencevFaza 3
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Vključevanje udeležencev
- University of Wisconsin, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Vključevanje udeležencevFaza 1
- University of Wisconsin - Carbone Cancer Center, Madison
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Vključevanje udeležencevFaza 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of Wisconsin-Madison Carbone Cancer Center, Madison
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Vključevanje udeležencevFaza 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Vključevanje udeležencevFaza 2
- University of Wisconsin, Madison
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Vključevanje udeležencevFaza 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of 18F-FFNP Breast PET/MRI
Vključevanje udeležencevFaza 2
- UW Carbone Cancer Center, Madison
Biomarkers to Detect Endocrine Therapy Resistance
Vključevanje udeležencevFaza 2
- UW Carbone Cancer Center, Madison
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Vključevanje udeležencevFaza 2
- University of Wisconsin Carbone Cancer Center, Madison
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Vključevanje udeležencevFaza 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Vključevanje udeležencevOpazovalna študija
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Vključevanje udeležencevFaza 4
- University of Wisconsin, Madison
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Vključevanje udeležencevFaza 1
- UW Carbone Cancer Center, Madison
Študije za Rak dojke v drugih mestih
- New York City, NY134 študij
- Houston, TX126 študij
- Boston, MA111 študij
- Nashville, TN80 študij
- Los Angeles, CA72 študij
- Edison, NJ68 študij
- St. Louis, MO64 študij
- Durham, NC63 študij
- Queens, NY63 študij
- Chicago, IL58 študij
- Philadelphia, PA56 študij
- Dallas, TX55 študij
Druge študije v Madison
- Rak prostate29 študij
- Kolorektalni rak22 študij
- Metastatski rak21 študij
- Nemalicelični pljučni rak16 študij
- Akutna mieločna levkemija16 študij
- Melanom15 študij
- Rak (vse vrste)14 študij
- Rak jajčnikov13 študij
- Rak želodca11 študij
- Rak pljuč10 študij
- Rak trebušne slinavke10 študij
- Množni mielom9 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.